{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiawn5m6nhrm6pzwk4xxvawvcgddrdk5t5j4iyqxc64lpelhxgfw6y",
    "uri": "at://did:plc:ox2kiwcr2xmn32p25g472pp7/app.bsky.feed.post/3mg42afh42sz2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiak32bh4e234puxk5nsx27ad62m6liy73lp6qiciwq63zmjsr3fpq"
    },
    "mimeType": "image/webp",
    "size": 60494
  },
  "path": "/releases/2026/03/260302030648.htm",
  "publishedAt": "2026-03-02T11:49:16.000Z",
  "site": "https://www.sciencedaily.com",
  "textContent": "Researchers are developing a two-part therapy for type 1 diabetes: lab-made insulin-producing cells paired with custom-engineered immune cells that protect them. The goal is to stop the immune system from destroying transplanted cells — without using immunosuppressive drugs. Backed by $1 million in funding, the team hopes to create a ready-to-use treatment that could work even for people who have had diabetes for years. The approach could transform how the disease is treated.",
  "title": "A bold new plan could finally cure type 1 diabetes"
}